ERYTHROMYCIN LACTOBIONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erythromycin Lactobionate, and what generic alternatives are available?
Erythromycin Lactobionate is a drug marketed by Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Nexus, and Teva Parenteral. and is included in five NDAs.
The generic ingredient in ERYTHROMYCIN LACTOBIONATE is erythromycin lactobionate. There are one hundred and three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the erythromycin lactobionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erythromycin Lactobionate
A generic version of ERYTHROMYCIN LACTOBIONATE was approved as erythromycin lactobionate by NEXUS on February 14th, 2022.
Summary for ERYTHROMYCIN LACTOBIONATE
| US Patents: | 0 |
| Applicants: | 5 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Clinical Trials: | 5 |
| Patent Applications: | 1,912 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ERYTHROMYCIN LACTOBIONATE at DailyMed |
Recent Clinical Trials for ERYTHROMYCIN LACTOBIONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Prof Dr Jan Tack | N/A |
| Cempra Inc | Phase 2/Phase 3 |
| Biomedical Advanced Research and Development Authority | Phase 2/Phase 3 |
Pharmacology for ERYTHROMYCIN LACTOBIONATE
| Drug Class | Macrolide Antimicrobial Macrolide |
| Physiological Effect | Decreased Sebaceous Gland Activity |
Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN LACTOBIONATE
US Patents and Regulatory Information for ERYTHROMYCIN LACTOBIONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Pharm | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 062604-002 | Nov 24, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Parenteral | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 063253-002 | Jul 30, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Baxter Hlthcare | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 062993-001 | May 9, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Parenteral | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 063253-001 | Jul 30, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Abraxis Pharm | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 062604-001 | Nov 24, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
